UNSPSC 51342001: Capravirine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C20H20Cl2N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VHC779598X, chemically known as 5-(3,5-dichlorophenyl)thio-4-isopropyl-1-(pyridin-4-yl-methyl)-1h-imidazol-2-yl-methyl carbamate but generally known as capravirine, which bears US NIH Compound Identifier 1783. European Medicines Agency schedules Capravirine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20328.

UNSPSC 51342001 Capravirine is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent state and local opportunities tagged under this code do not reflect capravirine specifically but rather related pharmaceutical inventory and emergency-response medications. State and local governments acquire pharmaceutical products through piggyback arrangements with established consortiums and direct competitive bidding processes, often as part of public health preparedness, emergency response, or community health initiatives. Issuing bodies include state health departments (such as the Illinois Department of Public Health) and county health agencies (such as Seminole County, Florida), which rely on both cooperative purchasing vehicles and open invitation-for-bid processes to source pharmaceutical supplies at volume.

Recent activity shows procurement concentrated in the Southeast and Midwest. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 for a 12-month initial term with renewal options, covering antibiotic tablets (Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg) under an invitation-for-bid process. Seminole County, Florida issued an IFB (IFB60459723LAS) with a July 26, 2026 response deadline seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, fixed-fee pricing, a two-year initial term with one-year renewal option, and potential FEMA funding contingency. Both opportunities require vendor compliance with drug-free workplace certification, E-Verify, and standard insurance coverage; neither applied explicit set-asides for disadvantaged enterprises.